UCB U.S. News

UCB's Global Corporate Website

Welcome to UCB in the United States

Healthcare Professionals

Patients

Investors

14 UCB announces U.S. FDA acceptance of new drug application and EMA MAA validation for zilucoplan for the treatment of generalized myasthenia gravis in adult patients

Read More Share:

Sep

26 UCB U.S. Headquarters in Atlanta Awarded Prestigious LEED Gold WELL Platinum Certifications

Read More Share:

Sep

22 UCB presents latest data from generalized myasthenia gravis portfolio at AANEM meeting

Read More Share:

Aug

17 UCB Partners in Health Economics and Outcomes Research to Evolve Solutions for Seizure Clusters

Read More Share:

May

10 UCB presents efficacy and safety results for zilucoplan and rozanolixizumab in generalized myasthenia gravis

Read More Share:

Mar

28 FINTEPLA® (fenfluramine) Oral Solution Now FDA Approved for Treatment of Seizures Associated with Lennox-Gastaut Syndrome (LGS)

Read More Share:

Mar

26 New Long-Term Complete Skin Clearance Data for Bimekizumab in Moderate to Severe Plaque Psoriasis Presented at the 2022 AAD Annual Meeting

Read More Share:

Mar

07 UCB Completes Acquisition of Zogenix, Inc.

Read More Share:

Feb

04 UCB announces positive data in myasthenia gravis with zilucoplan phase 3 study results

Read More Share:

Jan

21 Positive Top-Line Results for bimekizumab in Second Phase 3 Psoriatic Arthritis Study

Read More Share:

Categories

Archives

Nov

14

UCB announces U.S. FDA acceptance of new drug application and EMA MAA validation for zilucoplan for the treatment of generalized myasthenia gravis in adult patients

Sep

26

UCB U.S. Headquarters in Atlanta Awarded Prestigious LEED Gold WELL Platinum Certifications

Sep

22

UCB presents latest data from generalized myasthenia gravis portfolio at AANEM meeting

Aug

17

UCB Partners in Health Economics and Outcomes Research to Evolve Solutions for Seizure Clusters

May

10

UCB presents efficacy and safety results for zilucoplan and rozanolixizumab in generalized myasthenia gravis

Mar

28

FINTEPLA® (fenfluramine) Oral Solution Now FDA Approved for Treatment of Seizures Associated with Lennox-Gastaut Syndrome (LGS)

Mar

26

New Long-Term Complete Skin Clearance Data for Bimekizumab in Moderate to Severe Plaque Psoriasis Presented at the 2022 AAD Annual Meeting

Mar

07

UCB Completes Acquisition of Zogenix, Inc.

Feb

04

UCB announces positive data in myasthenia gravis with zilucoplan phase 3 study results

Jan

21

Positive Top-Line Results for bimekizumab in Second Phase 3 Psoriatic Arthritis Study

Choose Country

UCB in the U.S.

Innovation

Disease Areas

Sustainability

Newsroom

Contact

Categories

Archives

Nov

14

UCB announces U.S. FDA acceptance of new drug application and EMA MAA validation for zilucoplan for the treatment of generalized myasthenia gravis in adult patients

Sep

26

UCB U.S. Headquarters in Atlanta Awarded Prestigious LEED Gold WELL Platinum Certifications

Sep

22

UCB presents latest data from generalized myasthenia gravis portfolio at AANEM meeting

Aug

17

UCB Partners in Health Economics and Outcomes Research to Evolve Solutions for Seizure Clusters

May

10

UCB presents efficacy and safety results for zilucoplan and rozanolixizumab in generalized myasthenia gravis

Mar

28

FINTEPLA® (fenfluramine) Oral Solution Now FDA Approved for Treatment of Seizures Associated with Lennox-Gastaut Syndrome (LGS)

Mar

26

New Long-Term Complete Skin Clearance Data for Bimekizumab in Moderate to Severe Plaque Psoriasis Presented at the 2022 AAD Annual Meeting

Mar

07

UCB Completes Acquisition of Zogenix, Inc.

Feb

04

UCB announces positive data in myasthenia gravis with zilucoplan phase 3 study results

Jan

21

Positive Top-Line Results for bimekizumab in Second Phase 3 Psoriatic Arthritis Study

Choose Country

UCB in the U.S.

Innovation

Disease Areas

UCB Worldwide

Sustainability

Newsroom

Contact